Accendra Health (NYSE: ACH) CEO Ed Pesicka to retire as board begins search
Rhea-AI Filing Summary
Accendra Health, Inc. announced that President, Chief Executive Officer and Director Edward A. Pesicka plans to retire and step down from the Board by the end of 2026, or earlier if a successor is appointed. The company states that his decision is not due to any disagreement regarding operations, policies or practices.
The Board has an established succession planning process and has previously identified potential candidates, and will now evaluate and select the next President and CEO. Mr. Pesicka may serve in an advisory capacity beyond his retirement to support a smooth transition. Accendra also highlighted a previously announced investor conference call for second quarter 2026 results on August 10, 2026 at 8:00 a.m. E.T., accessible via webcast and dial-in numbers.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
succession planning process financial
divestiture financial
balance sheet optimization transaction financial
forward looking statements regulatory
Safe Harbor regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What leadership change did Accendra Health (ACH) disclose in this Form 8-K?
Did Edward A. Pesicka’s retirement decision involve any disagreement with Accendra Health (ACH)?
How is Accendra Health (ACH) handling CEO succession after Ed Pesicka’s retirement announcement?
Will Ed Pesicka remain involved with Accendra Health (ACH) after retiring as CEO?
When is Accendra Health’s (ACH) investor call for Q2 2026 results and how can it be accessed?
What recent strategic actions did Ed Pesicka highlight in his retirement comments about Accendra Health (ACH)?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State
or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
|
||
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On August 10, 2026, Accendra Health, Inc. (the “Company”) announced that Edward A. Pesicka, President, Chief Executive Officer & Director of the Company, notified the board of directors (the “Board”) of the Company of his intention to retire and step down from the Board by the end of 2026, or such earlier time as a successor is appointed. Mr. Pesicka’s decision to retire is not the result of any disagreement with the Company regarding any matter relating to the Company’s operations, policies or practices. The Board has commenced a process to evaluate and select the candidate to succeed Mr. Pesicka.
| Item 7.01 | Regulation FD Disclosure. |
On August 10, 2026, the Company issued a press release announcing Mr. Pesicka’s intent to retire.
The Company is furnishing the press release attached hereto as Exhibit 99.1 pursuant to Item 7.01 of Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press Release dated August 10, 2026 | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ACCENDRA HEALTH, INC. | |
| August 10, 2026 | /s/ Jonathan A. Leon |
| Jonathan A. Leon | |
| Executive Vice President and Chief Financial Officer |
Exhibit 99.1
Accendra Health’s Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search
RICHMOND, VA – August 10, 2026 – Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven years with the Company. Mr. Pesicka will also retire from the Company’s Board of Directors before the end of the year. The Board of Directors maintains a long-standing, robust succession planning process established to address officer succession. Through that process, the Board has previously identified potential candidates with the capabilities to succeed Mr. Pesicka. With Mr. Pesicka’s decision and announcement, the Board will leverage that preparation to comprehensively evaluate and select the Company’s next President and CEO. Mr. Pesicka may serve in an advisory capacity beyond his planned retirement date to help ensure a smooth and successful transition.
“Ed Pesicka has faithfully served our customers, teammates, and shareholders for nearly eight years,” commented Mark Beck, Chair of the Company’s Board of Directors. Mr. Beck continued, “Upon arrival, Ed quickly stabilized the company and then had to quickly pivot to lead the Company through a rapid expansion of personal protective equipment production during the pandemic in support of patients and caregivers, and he then guided our transformation into Accendra Health, a pure play home-based care company. Throughout his tenure, Ed strengthened our culture and built a great team, leaving a lasting legacy. On behalf of the Board of Directors, I want to express our most sincere gratitude to Ed for his commitment, significant contributions, and steady leadership. We wish him health and happiness in retirement.”
Mr. Pesicka commented, “The decision to retire is never easy, and there is never an ideal time. Having completed the divestiture of Owens & Minor, the balance sheet optimization transaction, and, most recently, changes to our management structure across the business, this is the best time to begin my next chapter. Through the continued leadership of our Board of Directors and the executive team, I am confident that this transition will be smooth, and I have no doubt that Accendra Health’s future is extremely bright. I want to thank the Board for their guidance, partnership, and trust over the last several years, and, most importantly, I want to thank every Accendra Health teammate for their dedication and hard work. I have been extremely proud to be part of the team.”
August 10 Investor Conference Call for Second Quarter 2026 Financial Results
As previously announced, Accendra Health will host a conference call for investors and analysts on August 10, 2026, at 8:00 a.m. E.T. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendrahealth.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.
1
Safe Harbor
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2026 financial results, our expectations regarding the performance of our business following the completion of the sale of the Products & Healthcare Services business, uncertainty about the time required to select and appoint the Company’s next President and CEO, our cost saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 20, 2026, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.accendrahealth.com. Given these risks and uncertainties, the Company can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. The Company specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
About Accendra Health
Accendra Health, Inc. (NYSE: ACH) is a leading nationwide provider of products, technology, and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care. To learn more about our broad portfolio of essentials for diabetes, sleep health, wound care, respiratory care, urology, and ostomy, visit www.accendrahealth.com.
2
CONTACT:
Investors
Will Parrish
Vice President, Strategy, Corporate Development, & Investor Relations
Investor.Relations@accendra.com
Media
Darla Turner
media@accendra.com
ACH-CORP
ACH-IR
SOURCE: Accendra Health, Inc.
3